Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor

This article was originally published in The Pink Sheet Daily

Executive Summary

Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.

You may also be interested in...



Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More

Allergan’s buyout of MAP Pharma is an unusual case of a deal centered on drug under the shadow of a “complete response” letter, but it’s not the only one. How does it compare to recent precedents.

NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets

The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.

Lanthio Pharma Raises €4.8 Million In Series A, Enters MorphoSys Pact

Dutch biotech Lanthio Pharma has entered into an alliance with MorphoSys to develop its lantipeptide technology, with the German drug-discovery company also participating in Lanthio Pharma’s Series A funding round.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel